Previous studies indicate that systemic treatment of IL7-Fc induces proliferation of CD8+ T cells [17] and improves anti-tumor responses by increasing CD8+ T cells in the periphery and by promoting the accumulation of CD8+ T cells in tumor tissues [18]. The gene discussed is CD8A; the disease is neoplasm.